We integrate deep-rooted biological expertise, apply advanced single-cell profiling technologies and leverage open-innovation strategies to accelerate the development of a repertoire of innovative antibody drugs that will soon transform patient care.

Robust Pipeline

We are developing a robust pipeline of first-in-class or best-in-class therapeutic antibodies that mobilize the human immune system to combat cancer, autoimmune disorders and other unmet medical needs around the world. We are actively progressing our own internal projects, while also establishing multiple partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions. Our current focus is on discovering and advancing novel therapeutic antibodies to target regulatory T cells and Myeloid-derived suppressor cells.

Unique Single-cell Platform

We apply our proprietary single-B-cell functional antibody discovery CelliGO™ platform to develop best-in-class therapeutics. Key platform advantages include:

  • Ultra-high-throughput antibody selection with millions of B-cells analyzed per campaign
  • Unprecedented single-cell resolution and ability to differentiate hit diversity
  • Deep mining ability of immune repertoire in a species agonistic manner
  • Enable to explore challenging targets such as multi-transmembrane proteins

Open Innovation and Partnerships

Open innovation strategies encourage external collaborations to help allocate resources more efficiently, improve product development and accelerate commercialization.

We believe in open innovation and continue to establish strategic partnerships and joint ventures with leading pharmaceutical and biotechnology companies, as well as academic institutions to better address unmet medical needs around the world. We are currently working together with many of the world’s top immunologists and oncologists to better understand the biological targets and the patient needs. All of our collaborations are streamlined for speed and driven by our scientific strategy.

Read our article in Drug Discovery Today for more information

Contact us today to learn more about our open-innovation strategies and partnerships

Publications and Posters

Our high scientific standards have been validated in numerous peer-reviewed publications and conference presentations.

Scientific Publication

Nature Biotechnology

Nature Biotechnology: Single-cell deep phenotyping of lgG-secreting cells for high-resolution immune monitoring
Read More

Scientific Poster

Antibody Discovery by Deep Mining of Immune Repertoires

Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study
Read More